09 May First Quarter Financial Report 2019
Gentian Diagnostics AS announces its results for the first quarter of 2019. The highlights include:
- Good start to the new fiscal year with sales revenues of MNOK 10.6 for the quarter.
- Record sales achieved for fCAL®turbo, our innovative biomarker for the diagnosis of inflammatory bowel disease.
- New scientific study results confirm GCAL as a promising biomarker for the diagnosis of bacterial infections.
Please find the report and results presentation enclosed. The documents is also available on Oslo Børs.
For further information, please contact:
CEO, Gentian Diagnostics
Cell Phone: +47 919 05 242
CFO, Gentian Diagnostics
Cell Phone: +47 919 06 525
Marked: Merkur Market
Kategori: HALVÅRSRAPPORTER OG REVISJONSBERETNINGER / UTTALELSER OM FORENKLET REVISORKONTROLL